Literature DB >> 20711324

Strattera: ups, downs, and emerging uses.

Elisa F Cascade1, Amir H Kalali, David Feifel.   

Abstract

Although overall prescribing of atomoxetine hydrochloride (HCI) (Strattera) continues to decline, recent anecdotal reports suggest emerging uses of the product in combination therapy. In this article we examine trends in atomoxetine (HCI) prescribing as well as use in combination with other psychotropic classes. An expert commentary is provided on the data.

Entities:  

Keywords:  ADHD; Strattera; atomoxetine hydrochloride; attention deficit hyperactivity disorder; augmentation; pharmacology

Year:  2007        PMID： 20711324      PMCID： PMC2921235     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN： 1550-5952


  4 in total

1.  Recent changes in prescriptions for antipsychotics in children and adolescents.

Authors:  Elisa F Cascade; Amir H Kalali; Joseph V Penn; David Feifel
Journal:  Psychiatry (Edgmont)       Date:  2006-09

2.  Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  David Michelson; Albert J Allen; Joan Busner; Charles Casat; David Dunn; Christopher Kratochvil; Jeffrey Newcorn; F Randy Sallee; R Bart Sangal; Keith Saylor; Scott West; Douglas Kelsey; Joachim Wernicke; Nancy J Trapp; Donald Harder
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

3.  Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Authors:  Douglas K Kelsey; Calvin R Sumner; Charles D Casat; Daniel L Coury; Humberto Quintana; Keith E Saylor; Virginia K Sutton; Jill Gonzales; Sandra K Malcolm; Kory J Schuh; Albert J Allen
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

4.  Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

Authors:  Joachim F Wernicke; Lenard Adler; Thomas Spencer; Scott A West; Albert J Allen; John Heiligenstein; Denái Milton; Dustin Ruff; W Jeffrey Brown; Douglas Kelsey; David Michelson
Journal:  J Clin Psychopharmacol       Date:  2004-02       Impact factor: 3.153
  4 in total
  1 in total

1.  Effectiveness and tolerability of atomoxetine in a real-world ADHD population: nonrandomized comparison with stimulants.

Authors:  Leo Bastiaens
Journal:  Psychiatry (Edgmont)       Date:  2007-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.